The note lists it under short covering, with OI down 2.8% and price up 1.0%.
Read this note →Alkem Laboratories Limited
NSE ALKEM BSE 539523 INE540L01014
0 filings · 0 analysed
5,398.50
-0.73%
over 5 years
-
Daily Derivative Insight Oct 08 2026 08 10 2026 08
The note lists it under short covering, with OI down 2.8% and price up 1.0%.
-
Pharma and Healthcare Q2FY27 Preview HSIE
The report expects 13% YoY revenue growth led by India formulations and Occlutech consolidation, but margins to stay under pressure from integration and higher costs.
-
Options-on-radar idea to buy the 5250 CE on short covering, with target 164 and SL 115.
-
The report forecasts Alkem sales growth of 9.5% YoY and EBITDA growth of 8.4% YoY with PAT declining 13.0% YoY in 2QFY27.
Prices from Yahoo Finance, NSE close, delayed — indicative only, not for dealing. Solid markers sit on the exchange's own timestamp.
Targets, and what happened next
What each house published, and where the price has gone since. Orivam issues no calls of its own and takes no view on these.
| House | Published | Call | Entry | Target | Now | Progress | Standing |
|---|---|---|---|---|---|---|---|
| HDFC Securities | 07 Oct 2026, 15:25 | long | 5,350.50 | 6,000.00 | 5,297.00 | -8% | open by 2027-10-07 |
Deadlines: 0 stated by the house, the rest set by Orivam’s convention — ten trading days for a technical call, twelve months for a price target. A target with no date cannot be judged, so one has to be chosen.
What the desks said
The report expects 13% YoY revenue growth led by India formulations and Occlutech consolidation, but margins to stay under pressure from integration and higher costs.
Read this note →Options-on-radar idea to buy the 5250 CE on short covering, with target 164 and SL 115.
Read this note →The report forecasts Alkem sales growth of 9.5% YoY and EBITDA growth of 8.4% YoY with PAT declining 13.0% YoY in 2QFY27.
Read this note →Announcement timeline
No filings stored for this company yet.
Never miss the next one.
Orivam emails what the research desks published each trading morning, attributed and linked to the original notes. Free.
Get the daily brief